Mostrando 10 resultados de: 20
Filtros aplicados
Publisher
Pharmacogenomics(8)
Pharmacogenomics Journal(3)
Expert Opinion on Drug Metabolism and Toxicology(2)
British Journal of Clinical Pharmacology(1)
Current Drug Targets(1)
Área temáticas
Farmacología y terapéutica(14)
Enfermedades(11)
Bioquímica(7)
Fisiología humana(5)
Fisiología y materias afines(3)
Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
ArticleAbstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)Palabras claves:Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 variation, behaviour and psychopathology: Implications for pharmacogenomics-guided clinical trials
ArticleAbstract: Individual and population differences in polymorphic cytochrome P450 enzyme function have been knownPalabras claves:clinical trials, CYP2D6, endogenous compound metabolism, personality traits, pharmacogenetics, psychopathologyAutores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopus